<?xml version="1.0" encoding="UTF-8"?>
<VIOLIN>
	<pathogen pathogen_id="pathogen51">
		<pathogen_name>Japanese encephalitis virus</pathogen_name>
		<taxon_id>11072</taxon_id>
		<pathogenesis refs="">Japanese encephalitis virus infects the lumen of the endoplasmic reticulum and rapidly accumulates substantial amounts of viral proteins.</pathogenesis>
		<disease_name>Japanese encephalitis</disease_name>
		<protective_immunity refs="reference720 reference1160">Infection with JEV confers life-long immunity (Wiki: Japanese encephalitis). For JE, both arms have been considered to be important for protection from the disease, since passive transfer of neutralizing antibodies or virus-specific T cells including CTLs can protect mice from a lethal challenge (Konishi et al., 2003).</protective_immunity>
		<host_range refs="">Domestic pigs and wild birds are reservoirs of the virus; transmission to humans may cause severe symptoms.</host_range>
		<introduction refs="reference720">Japanese encephalitis virus is a virus from the family Flaviviridae. It causes the mosquito-borne Japanese encephalitis. Japanese encephalitis is the leading cause of viral encephalitis in Asia, with 30,000–50,000 cases reported annually. Case-fatality rates range from 0.3% to 60% and depends on the population and on age. Rare outbreaks in U.S. territories in Western Pacific have occurred. This disease often occurs in rural areas but not usually in urban areas. Severe rigors, fever, headache and malaise are non-specific symptoms for the first week. Signs which develop during the acute encephalitic stage include neck rigidity, cachexia, hemiparesis, convulsions, and fever. Mental retardation developed from this disease usually leads to coma. Mortality of this disease varies but is generally much higher in children (Wiki: Japanese encephalitis).</introduction>
	</pathogen>

	<host host_id="host55">
		<common_name>Baboon</common_name>
		<scientific_name>Papio cynocephalus</scientific_name>
		<taxon_id>9556</taxon_id>
    </host>
	<host host_id="host43">
		<common_name>Bank vole</common_name>
		<scientific_name>Clethrionomys glareolus</scientific_name>
		<taxon_id>447135</taxon_id>
    </host>
	<host host_id="host31">
		<common_name>Bear</common_name>
		<scientific_name>Ursus americanus</scientific_name>
		<taxon_id>9643</taxon_id>
    </host>
	<host host_id="host51">
		<common_name>Birds</common_name>
		<scientific_name>Passeroidea</scientific_name>
		<taxon_id>175121</taxon_id>
    </host>
	<host host_id="host35">
		<common_name>Brown Trout</common_name>
		<scientific_name>Salmo trutta</scientific_name>
		<taxon_id>8032</taxon_id>
    </host>
	<host host_id="host30">
		<common_name>Buffalo</common_name>
		<scientific_name>Bison bison</scientific_name>
		<taxon_id>9901</taxon_id>
    </host>
	<host host_id="host53">
		<common_name>Carnivores</common_name>
		<scientific_name>Vulpes</scientific_name>
		<taxon_id>9625</taxon_id>
    </host>
	<host host_id="host37">
		<common_name>Cat</common_name>
		<scientific_name>Felis catus</scientific_name>
		<taxon_id>9685</taxon_id>
    </host>
	<host host_id="host52">
		<common_name>Catfishes</common_name>
		<scientific_name>Siluriformes</scientific_name>
		<taxon_id>7995</taxon_id>
    </host>
	<host host_id="host12">
		<common_name>Cattle</common_name>
		<scientific_name>Bos taurus</scientific_name>
		<taxon_id>9913</taxon_id>
    </host>
	<host host_id="host8">
		<common_name>Chicken</common_name>
		<scientific_name>Gallus gallus</scientific_name>
		<taxon_id>9031</taxon_id>
    </host>
	<host host_id="host42">
		<common_name>Chimpanzee</common_name>
		<scientific_name>Pan troglodytes</scientific_name>
		<taxon_id>9598</taxon_id>
    </host>
	<host host_id="host26">
		<common_name>chinchillas</common_name>
		<scientific_name>Chinchillidae</scientific_name>
		<taxon_id>10150</taxon_id>
    </host>
	<host host_id="host24">
		<common_name>Copper Pheasant</common_name>
		<scientific_name>Syrmaticus soemmerringii</scientific_name>
		<taxon_id>9067</taxon_id>
    </host>
	<host host_id="host29">
		<common_name>Deer</common_name>
		<scientific_name>Cervus elaphus</scientific_name>
		<taxon_id>9860</taxon_id>
    </host>
	<host host_id="host32">
		<common_name>Deer mouse</common_name>
		<scientific_name>Peromyscus maniculatus</scientific_name>
		<taxon_id>10042</taxon_id>
    </host>
	<host host_id="host36">
		<common_name>Dog</common_name>
		<scientific_name>Canis familiaris</scientific_name>
		<taxon_id>9615</taxon_id>
    </host>
	<host host_id="host9">
		<common_name>Ducks</common_name>
		<scientific_name>Anas</scientific_name>
		<taxon_id>8835</taxon_id>
    </host>
	<host host_id="host19">
		<common_name>Ferret</common_name>
		<scientific_name>Mustela putorius furo</scientific_name>
		<taxon_id>9669</taxon_id>
    </host>
	<host host_id="host48">
		<common_name>Fish</common_name>
		<scientific_name>Hyperotreti</scientific_name>
		<taxon_id>117565</taxon_id>
    </host>
	<host host_id="host41">
		<common_name>Gerbil</common_name>
		<scientific_name>Gerbillina</scientific_name>
		<taxon_id>10045</taxon_id>
    </host>
	<host host_id="host13">
		<common_name>Goat</common_name>
		<scientific_name>Capra hircus</scientific_name>
		<taxon_id>9925</taxon_id>
    </host>
	<host host_id="host47">
		<common_name>Gray wolf</common_name>
		<scientific_name>Canis lupus</scientific_name>
		<taxon_id>9612</taxon_id>
    </host>
	<host host_id="host7">
		<common_name>Guinea pig</common_name>
		<scientific_name>Cavia porcellus</scientific_name>
		<taxon_id>10141</taxon_id>
    </host>
	<host host_id="host16">
		<common_name>Hamster</common_name>
		<scientific_name>Mesocricetus auratus</scientific_name>
		<taxon_id>10036</taxon_id>
    </host>
	<host host_id="host18">
		<common_name>Horse</common_name>
		<scientific_name>Equus caballus</scientific_name>
		<taxon_id>9796</taxon_id>
    </host>
	<host host_id="host2">
		<common_name>Human</common_name>
		<scientific_name>Homo sapiens</scientific_name>
		<taxon_id>9606</taxon_id>
    </host>
	<host host_id="host39">
		<common_name>Macaque</common_name>
		<scientific_name>Macaca fascicularis</scientific_name>
		<taxon_id>9541</taxon_id>
    </host>
	<host host_id="host40">
		<common_name>Mongolian Gerbil</common_name>
		<scientific_name>Meriones unguiculatus</scientific_name>
		<taxon_id>10047</taxon_id>
    </host>
	<host host_id="host5">
		<common_name>Monkey</common_name>
		<scientific_name>Platyrrhini</scientific_name>
		<taxon_id>9479</taxon_id>
    </host>
	<host host_id="host3">
		<common_name>Mouse</common_name>
		<scientific_name>Mus musculus</scientific_name>
		<taxon_id>10090</taxon_id>
    </host>
	<host host_id="host59">
		<common_name>None</common_name>
		<scientific_name>None</scientific_name>
		<taxon_id></taxon_id>
    </host>
	<host host_id="host50">
		<common_name>Parrot</common_name>
		<scientific_name>Psittacidae</scientific_name>
		<taxon_id>9224</taxon_id>
    </host>
	<host host_id="host15">
		<common_name>Pig</common_name>
		<scientific_name>Sus scrofa</scientific_name>
		<taxon_id>9823</taxon_id>
    </host>
	<host host_id="host6">
		<common_name>Rabbit</common_name>
		<scientific_name>Oryctolagus cuniculus</scientific_name>
		<taxon_id>9986</taxon_id>
    </host>
	<host host_id="host45">
		<common_name>Rainbow trout</common_name>
		<scientific_name>Oncorhynchus mykiss</scientific_name>
		<taxon_id>8022</taxon_id>
    </host>
	<host host_id="host4">
		<common_name>Rat</common_name>
		<scientific_name>Rattus</scientific_name>
		<taxon_id>10114</taxon_id>
    </host>
	<host host_id="host34">
		<common_name>Raven</common_name>
		<scientific_name>Corvus corax</scientific_name>
		<taxon_id>56781</taxon_id>
    </host>
	<host host_id="host54">
		<common_name>sei whale</common_name>
		<scientific_name>Balaenoptera borealis</scientific_name>
		<taxon_id>9768</taxon_id>
    </host>
	<host host_id="host17">
		<common_name>Sheep</common_name>
		<scientific_name>Ovis aries</scientific_name>
		<taxon_id>9940</taxon_id>
    </host>
	<host host_id="host28">
		<common_name>Squirrel</common_name>
		<scientific_name>Spermophilus richardsonii</scientific_name>
		<taxon_id>37591</taxon_id>
    </host>
	<host host_id="host44">
		<common_name>Tree shrew</common_name>
		<scientific_name>Tupaiidae</scientific_name>
		<taxon_id>9393</taxon_id>
    </host>
	<host host_id="host49">
		<common_name>Trouts, salmons &amp; chars</common_name>
		<scientific_name>Salmoninae</scientific_name>
		<taxon_id>504568</taxon_id>
    </host>
	<host host_id="host38">
		<common_name>Turkey</common_name>
		<scientific_name>Meleagris gallopavo</scientific_name>
		<taxon_id>9103</taxon_id>
    </host>
	<host host_id="host33">
		<common_name>Vole</common_name>
		<scientific_name>Microtus ochrogaster</scientific_name>
		<taxon_id>79684</taxon_id>
    </host>
	<host host_id="host27">
		<common_name>Water buffalo</common_name>
		<scientific_name>Bubalus bubalis</scientific_name>
		<taxon_id>391902</taxon_id>
    </host>
	<vaccine vaccine_id="vaccine4268">
		<vaccine_name>ALVAC-JEV</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004777</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3289">Poxvirus-vectored vaccines for Japanese encephalitis (JE), NYVAC-JEV and ALVAC-JEV(Raengsakulrach et al., 1999).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1824" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3289">The vaccines were given to four monkeys each on study days 0 and 28 along with saline placebo on day 7. For controls, the licensed BIKEN JE vaccine and a saline placebo were given to other groups of four monkeys on days 0, 7, and 28 (Raengsakulrach et al., 1999).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3289">This study suggests that the NYVAC-JEV and ALVAC-JEV vaccines are safe and immunogenic in monkeys and that the NYVAC-JEV and BIKEN vaccines are effective in protecting monkeys from encephalitis (Raengsakulrach et al., 1999).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3289">Two months after the booster dose, all 16 monkeys were challenged intranasally with one 90% effective dose of JEV strain KE-93 (AP61-1, C6/36-1, Mm-1, SM-2) (Raengsakulrach et al., 1999).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine741">
		<vaccine_name>Ixiaro</vaccine_name>
		<proper_name>Japanese Encephalitis Vaccine, Inactivated, Adsorbed</proper_name>
		<brand_name>IXIARO</brand_name>
		<manufacturer>Valneva SE</manufacturer>
		<vo_id>VO_0011558</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed>USA, Canada</location_licensed>
		<description refs=""></description>
		<adjuvant refs="">Aluminum hydroxide</adjuvant>
		<storage refs="">Store in a refrigerator at 2° to 8° C (35° to 46° F).  Do not freeze.</storage>
		<virulence refs=""></virulence>
		<preparation refs="">JEV strain SA14-14-2 is propagated in Vero cells, and harvested. The harvested virus suspension is treated with protamine sulfate to remove contaminating DNA and proteins and centrifuged. Virus is inactivated by formaldehyde and aluminum hydroxide is added Ref917:FDA: Ixiaro].</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4273">
		<vaccine_name>Japanese encephalitis virus (JEV)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1037">
		<vaccine_name>Japanese encephalitis virus DNA vaccine encoding E protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011353</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>Expression vectors pcDL-SRα296 and pCAGGS</vector>
		<route>Intravenous injection (i.v.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intravenous injection (i.v.)</route>
		<antigen refs="">Japanese encephalitis virus PrM and E protein</antigen>

		<gene_engineering gene_engineering_id="gene_engineering524" gene_id="gene555">
			<type>DNA vaccine construction</type>
			<description refs="reference1158">Plasmid pSLKJ12 contains the premembrane signal sequence as well as the premembrane (PrM) and envelope (E) genes of the Sagayama strain of JEV. The viral sequence, spanning nucleotides 408 to 2477, was retrieved from this plasmid by PstI-EcoRI digestion. The fragment was cloned into the eukaryotic expression vectors pcDL-SRα296 and pCAGGS, generously provided by Y. Takebe (Laboratory of Molecular Virology and Epidemiology, AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan) and J. Miyazaki (Division of Stem Cell Regulation Research, G6, Osaka University Medical School, Suita, Osaka, Japan), respectively. They are purified and designated pSRαJ12 and pCAGJ12, respectively (Zhao et al., 2003).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering525" gene_id="gene554">
			<type>DNA vaccine construction</type>
			<description refs="reference1158">Plasmid pSLKJ12 contains the premembrane signal sequence as well as the premembrane (PrM) and envelope (E) genes of the Sagayama strain of JEV. The viral sequence, spanning nucleotides 408 to 2477, was retrieved from this plasmid by PstI-EcoRI digestion. The fragment was cloned into the eukaryotic expression vectors pcDL-SRα296 and pCAGGS, generously provided by Y. Takebe (Laboratory of Molecular Virology and Epidemiology, AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan) and J. Miyazaki (Division of Stem Cell Regulation Research, G6, Osaka University Medical School, Suita, Osaka, Japan), respectively (Zhao et al., 2003).</description>
		</gene_engineering>
		<host_response host_response_id="host_response791" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1158">For the protection test, 3-week-old female BALB/c mice were inoculated with either 50, 5, or 0.5 μg of the mixture on days 0 and 9 intravenously or intradermally (Zhao et al., 2003).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1158">Researchers established a simple and effective method for DNA immunization against Japanese encephalitis virus (JEV) infection with plasmids encoding the viral PrM and E proteins and colloidal gold.   After being inoculated twice, BALB/c mice were found to resist challenge with 100,000 times the 50% lethal dose (LD(50)) of JEV (Beijing-1 strain) even when immunized with a relatively small dose of 0.5 micro g of plasmid DNA (Zhao et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1158">On day 22, all immunized mice were challenged by an intraperitoneal injection of 100,000 times the LD50 of JEV (Beijing-1 strain, 0.15 ml), at which time they were simultaneously inoculated intracerebrally with 25 μl of saline into the right hemisphere of their brains with a 27-gauge one-stop needle (Top Injection Needle, Tokyo, Japan) (Zhao et al., 2003).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1033">
		<vaccine_name>Japanese encephalitis virus DNA vaccine encoding NS1 (pUSK-NS1)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011500</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pUSK</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">Japanese encephalitis virus NS1</antigen>

		<gene_engineering gene_engineering_id="gene_engineering520" gene_id="gene556">
			<type>DNA vaccine construction</type>
			<description refs="reference1159">NS1 gene of Japanese encephalitis virus (JEV) SA14-14-2 strain was produced by reverse transcriptase-mediated PCR (RT-PCR) and was cloned into vector pUSK to form recombinant plasmid (designed as pUSK-NS1) (Xu et al., 2004).</description>
		</gene_engineering>
		<host_response host_response_id="host_response787" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1159">Ten 6-week-old Balb/c mice and eight 2-days old piglets were immunized with 5.0 log10pfu of the TK−/gG−/NS1+ mutant, while another equal number of animal in control groups with PBS (Xu et al., 2004).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1159">Balb/c mice and swine vaccinated with TK(-)/gG(-)/NS1(+) expressing NS1 protein of JEV could confer protective immunity against lethal challenge of the virulent PRV Ea strain and develop a good humoral and cellular immune response against JEV (Xu et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1159">The challenge was performed with PRV Ea strain at a concentration of 6.5 log10pfu (LD50=10−4.5) at day 7 for mice and day 14 for piglets post-vaccination (Xu et al., 2004).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1067">
		<vaccine_name>Japanese encephalitis virus DNA vaccine encoding PrM</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011345</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>Expression vectors pcDL-SRα296 and pCAGGS</vector>
		<route>Intravenous injection (i.v.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intravenous injection (i.v.)</route>
		<antigen refs="">envelope protein</antigen>

		<gene_engineering gene_engineering_id="gene_engineering554" gene_id="gene555">
			<type>DNA vaccine construction</type>
			<description refs="reference1158">Plasmid pSLKJ12 contains the premembrane signal sequence as well as the premembrane (PrM) and envelope (E) genes of the Sagayama strain of JEV. The viral sequence, spanning nucleotides 408 to 2477, was retrieved from this plasmid by PstI-EcoRI digestion. The fragment was cloned into the eukaryotic expression vectors pcDL-SRα296 and pCAGGS, generously provided by Y. Takebe (Laboratory of Molecular Virology and Epidemiology, AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan) and J. Miyazaki (Division of Stem Cell Regulation Research, G6, Osaka University Medical School, Suita, Osaka, Japan), respectively. They are purified and designated pSRαJ12 and pCAGJ12, respectively (Zhao et al., 2003).</description>
		</gene_engineering>
		<host_response host_response_id="host_response824" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1158">For the protection test, 3-week-old female BALB/c mice were inoculated with either 50, 5, or 0.5 μg of the mixture on days 0 and 9 intravenously or intradermally (Zhao et al., 2003).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1158">Researchers established a simple and effective method for DNA immunization against Japanese encephalitis virus (JEV) infection with plasmids encoding the viral PrM and E proteins and colloidal gold.   After being inoculated twice, BALB/c mice were found to resist challenge with 100,000 times the 50% lethal dose (LD(50)) of JEV (Beijing-1 strain) even when immunized with a relatively small dose of 0.5 micro g of plasmid DNA (Zhao et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1158">On day 22, all immunized mice were challenged by an intraperitoneal injection of 100,000 times the LD50 of JEV (Beijing-1 strain, 0.15 ml), at which time they were simultaneously inoculated intracerebrally with 25 μl of saline into the right hemisphere of their brains with a 27-gauge one-stop needle (Top Injection Needle, Tokyo, Japan) (Zhao et al., 2003).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3943">
		<vaccine_name>Japanese encephalitis virus DNA Vaccine P-JEV</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004586</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3.1/V5-His-P-JEV [Ref2719:Kulkarni et al., 2012]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1560" gene_id="gene554">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1603" gene_id="gene556">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1604" gene_id="gene1727">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1590" host_id="host3">
			<immune_response refs="reference2719">Anti-JEV antibodies were detectable in all mouse groups 31 days after immunization. Levels of these antibodies increased after the first booster immunization and were further enhanced after the second booster dose. Following the challenge, pcDNA3.1/V5-His-P-JEV immunized mice showed significantly enhanced JEV antibody titres (Kulkarni et al., 2012).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference2719">Control mice received 1 μg of pcDNA3.1/V5-His plasmid per dose. While same amount of recombinant plasmid, pcDNA3.1/V5-His-P-JEV was used to immunize the experimental group. Groups of BALB/c mice (n = 10), received two booster doses with equal amount of DNA after every 2 weeks (Kulkarni et al., 2012).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2719">Approximately 83% of mice immunized with the vaccine survived the challenge injection (Kulkarni et al., 2012).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference2719">At 6 weeks after immunization, mice were challenged with lethal dose of 100LD50 with JEV 733913 strain by intraperitonial route, followed by 1% starch by the intracerebral route to breach the blood brain barrier (Kulkarni et al., 2012).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3944">
		<vaccine_name>Japanese encephalitis virus DNA Vaccine pCJ-3/E encoding E</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004587</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pCJ-3/E [Ref2720:Wu et al., 2006]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1561" gene_id="gene554">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1591" host_id="host3">
			<immune_response refs="reference2720">The vaccine enhanced the production of higher titers of neutralizing antibodies, and  generated both cellular and humoral immunity (Wu et al., 2006).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference2720">All mice were immunized intramuscularly at 6 to 8 weeks of age. Groups of five mice were anesthetized and injected three times at 3-week intervals with 100 μg of DNA (Wu et al., 2006).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2720">In terms of survival rates of immunized mice challenged with JEV virus at week 16, 100% protection was seen with pCJ-3/E-immunized mice (Wu et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference2720">For a lethal challenge experiment, C3H/HeN mice were injected intraperitoneally with 50 times the LD50 of JEV Beijing-1 and intracerebrally with PBS (Wu et al., 2006).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1034">
		<vaccine_name>Japanese encephalitis virus DNA vaccine pUJENS3</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011501</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pUBIQ vector</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">Japanese encephalitis virus non-structural protein NS3</antigen>

		<gene_engineering gene_engineering_id="gene_engineering521" gene_id="gene557">
			<type>DNA vaccine construction</type>
			<description refs="reference1160">Amplified DNA fragments containing the NS3 gene was ligated to the pUBIQ vector at the EcoRI/XbaI site to construct pUJENS3 (Konishi et al., 2003).</description>
		</gene_engineering>
		<host_response host_response_id="host_response788" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1160">Four-to-six-week-old male BALB/c mice were immunized intramuscularly (i.m.) with 100 μg of plasmid DNA one to three times at intervals of 2 weeks. For evaluation of CTL induction, spleens were collected from groups of two immunized mice 2–4 weeks after the last immunization (Konishi et al., 2003).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1160">Researchers constructed plasmid DNAs encoding JE virus proteins.  Cytotoxic T lymphocytes (CTLs) were induced by NS3 in a mouse model.  Three immunizations with pUJENS3 provided a 50% partial protection from a lethal dose of JE virus (Konishi et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1160">For evaluation of protective efficacy, groups of 6–12 immunized mice were bled retroorbitally for evaluating pre-challenge serum neutralizing antibody titers, and then challenged i.p. with 100 or 400 LD50 of the P3 strain of JE virus, 6 weeks after the first immunization. Mice were observed for 21 days, and surviving mice were bled for evaluating post-challenge serum neutralizing antibody titers. For monitoring virus load following challenge, groups of 18 immunized mice were challenged with 100 LD50 of the P3 strain, and 600–700 μl of blood and the whole brain were collected 1 h (day 0) or consecutive 5 days (days 1–5) following challenge from 3 mice per day per group (Konishi et al., 2003).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1036">
		<vaccine_name>Japanese encephalitis virus DNA vaccine pUJENS5</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011352</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pUBIQ vector</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">Japanese encephalitis virus NS5</antigen>

		<gene_engineering gene_engineering_id="gene_engineering523" gene_id="gene558">
			<type>DNA vaccine construction</type>
			<description refs="reference1160">Amplified DNA fragments containing the NS5 gene was ligated to the pUBIQ8 vector at the BspEI and/or XbaI sites to construct pUJENS5 (Konishi et al., 2003).</description>
		</gene_engineering>
		<host_response host_response_id="host_response789" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1160">Four-to-six-week-old male BALB/c mice were immunized intramuscularly (i.m.) with 100 μg of plasmid DNA one to three times at intervals of 2 weeks. For evaluation of CTL induction, spleens were collected from groups of two immunized mice 2–4 weeks after the last immunization (Konishi et al., 2003).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1160">Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS5 in a mouse model. Three immunizations with pUJENS5 provided a 57% partial protection from a lethal dose of JE virus (Konishi et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1160">For evaluation of protective efficacy, groups of 6–12 immunized mice were bled retroorbitally for evaluating pre-challenge serum neutralizing antibody titers, and then challenged i.p. with 100 or 400 LD50 of the P3 strain of JE virus, 6 weeks after the first immunization. Mice were observed for 21 days, and surviving mice were bled for evaluating post-challenge serum neutralizing antibody titers. For monitoring virus load following challenge, groups of 18 immunized mice were challenged with 100 LD50 of the P3 strain, and 600–700 μl of blood and the whole brain were collected 1 h (day 0) or consecutive 5 days (days 1–5) following challenge from 3 mice per day per group (Konishi et al., 2003).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1027">
		<vaccine_name>Japanese encephalitis virus vaccine BV-G-E</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011516</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>baculovirus pseudotyped with vesicular stomatitis virus glycoprotein (VSVG)</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">Japanese encephalitis virus envelope protein</antigen>

		<gene_engineering gene_engineering_id="gene_engineering514" gene_id="gene554">
			<type>Recombinant vector construction</type>
			<description refs="reference1157">Recombinant pseudotype baculovirus (BV-G-E) was generated by inserting JEV E gene fragment into pFastBac-VSV/G vector. BALB/c mice were immunized with BV-G-E and challenged with JEV wild-type strain. The neutralization antibody, interferon (IFN)- expression and release, and survival rate were analysed and compared with the group of immunized with inactivated vaccine and DNA vaccine (pc-E) encoding the same gene of JEV (Li et al., 2009).</description>
		</gene_engineering>
		<host_response host_response_id="host_response781" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1157">Four-week old female BALB/c mice (purchased from the Animal Centre, Institute of Medicine (Hubei Province, China) were randomly divided into seven groups (15 mice per group). Three groups were injected intramuscularly (i.m.) with 100 µl of PBS containing 1 × 10^8, 1 × 10^9 and 1 × 10^10 PFU of BV-G-E, respectively. The other three groups were injected intramuscularly with 100 µl of PBS containing 1 × 10^10 PFU of BV-G-EGFP or 100 µg of pc-E (a DNA vaccine construct expressing E protein) or 100 µl inactivated vaccine. The last group was used as a negative control by intramuscularly injecting 100 µl of PBS. Booster immunizations were identically performed 3 weeks later (Li et al., 2009).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1157">Researchers constructed a recombinant pseudotype baculovirus encoding the JEV envelope (E) protein and demonstrated that it could elicit high protective immunity in mice.  Intramuscular injections of BV-G-E at various doses into mice produced higher levels of JEV-specific neutralizing antibodies, IFN-gamma and better protective efficacy against a lethal challenge with JEV than that of pc-E. Furthermore, BV-G-E could elicit a higher level of cellular immunity response and provide equal protective efficacy against JEV challenge compared to inactivated vaccine (Li et al., 2009).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1157">A subset of immunized mice was intraperitoneally (i.p.) challenged with 105 PFU of wild-type JEV P3 in 0.1 ml at 6 weeks following the initial immunization. Mouse mortality was monitored daily for 3 weeks (Li et al., 2009).</challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response278" gene_id="gene1">
			    <description refs="reference1157">An evident dose-dependent pattern of IFN-gamma production could be observed in mice immunized with BV-G-E. As expected, no significant production of IFN-γ was detected in PBS-inoculated mice. Interestingly, the mean relative IFN-γ mRNA expression in the group of BV-G-EGFP was also significantly higher than that of pc-E vaccinated mice in splenocytes (Li et al., 2009).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine331">
		<vaccine_name>JE-Vax</vaccine_name>
		<proper_name>Japanese Encephalitis Virus Vaccine Inactivated</proper_name>
		<brand_name>JE-Vax</brand_name>
		<manufacturer>Research Foundation for Microbial Diseases of Osaka University, License #1156</manufacturer>
		<vo_id>VO_0000066</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed>USA</location_licensed>
		<description refs="">JE-VAX is a sterile, lyophilized vaccine for subcutaneous use Ref747:FDA: Jevax].</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">The vaccine should be stored at 2° to 8°C (35° to 46°F). DO NOT FREEZE. After reconstitution the vaccine should be stored at 2° to 8°C (35° to 46°F) and used within 8 hours. DO NOT FREEZE RECONSTITUTED VACCINE.</storage>
		<virulence refs=""></virulence>
		<preparation refs="reference747">JE-VAX is prepared by inoculating mice intracerebrally with Japanese encephalitis (JE) virus, “Nakayama-NIH” strain. Infected brains are harvested and homogenized in PBS, pH 8.0. The homogenate is centrifuged and the supernatant inactivated with formaldehyde, then processed to yield a partially purified, inactivated virus suspension. This is further purified by ultra-centrifugation through 40% w/v sucrose. The suspension is then lyophilized. Thimerosal (mercury derivative) is added as a preservative to a final concentration of 0.007%. The diluent sterile water for Injection contains no preservative. Each 1.0 mL dose contains approximately 500 μg of gelatin, less than 100 μg of formaldehyde, less than 0.0007% v/v Polysorbate 80, and less than 50 ng of mouse serum protein. No myelin basic protein can be detected at the detection threshold of the assay (&lt;2 ng/mL). Prior to reconstitution, the vaccine is a white caked powder. After reconstitution, the vaccine is a colorless transparent liquid (FDA: JE-Vax).</preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="">Inactivated Japanese encephalitis (JE) virus “Nakayama-NIH” strain</antigen>
		<host_response host_response_id="host_response426" host_id="host2">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference747">In a placebo-controlled, randomized clinical trial in Thai children, sponsored by the US Army.  In this trial, children between 1 and 14 years of age received BIKEN monovalent Nakayama-NIH strain (n = 21,628) or a bivalent vaccine containing the Nakayama-NIH and Beijing JE virus strains (n = 22,080) or tetanus toxoid as a placebo (n = 21,516) (FDA: JE-Vax).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference747">One case (5 cases/100,000) of Japanese encephalitis (JE) occurred in the monovalent vaccine group, one case (5 cases/100,000) in the bivalent vaccine group, and 11 cases (51 cases/100,000) in the placebo group. The observed efficacy of both monovalent and bivalent vaccines was 91% (FDA: JE-Vax).</protection_efficacy>
			<side_effects refs="">Side effects that were reported included: headache, sore arm, rash, and swelling</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs="">JE-VAX should be considered for use in persons who plan to reside in or travel to areas where JE is endemic or epidemic during a transmission season</description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4267">
		<vaccine_name>NYVAC-JEV</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004776</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3289">Poxvirus-vectored vaccines for Japanese encephalitis (JE), NYVAC-JEV and ALVAC-JEV(Raengsakulrach et al., 1999).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1823" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3289">The vaccines were given to four monkeys each on study days 0 and 28 along with saline placebo on day 7. For controls, the licensed BIKEN JE vaccine and a saline placebo were given to other groups of four monkeys on days 0, 7, and 28 (Raengsakulrach et al., 1999).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3289">This study suggests that the NYVAC-JEV and ALVAC-JEV vaccines are safe and immunogenic in monkeys and that the NYVAC-JEV and BIKEN vaccines are effective in protecting monkeys from encephalitis (Raengsakulrach et al., 1999).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3289">Two months after the booster dose, all 16 monkeys were challenged intranasally with one 90% effective dose of JEV strain KE-93 (AP61-1, C6/36-1, Mm-1, SM-2) (Raengsakulrach et al., 1999).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4274">
		<vaccine_name>NYVAC-JEV- prM/E/ NS1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004780</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3293">Highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1733" gene_id="gene555">
			<type>Recombinant vector construction</type>
			<description refs="reference3293">A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1734" gene_id="gene556">
			<type>Recombinant vector construction</type>
			<description refs="reference3293">A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1735" gene_id="gene554">
			<type>Recombinant protein preparation</type>
			<description refs="reference3293">A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1825" host_id="host15">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3293">The recombinant viruses were tested as vaccine candidates in pigs, a natural host of JEV. JEV-neutralizing and hemagglutination-inhibiting antibodies appeared in swine sera 7 days after immunization with 108 PFU of the recombinant viruses and increased after a second dose at 28 days (Konishi et al., 1992).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3293">The JEV levels detected in the serum after JEV challenge were significantly reduced in animals inoculated with the recombinant viruses (Konishi et al., 1992).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3293">JEV challenge (d56) of the swine with 2 × 10^8 PFU of JEV  (Konishi et al., 1992).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<gene gene_id="gene554">
        <gene_name>E</gene_name>
        <strain>Japanese encephalitis virus</strain>
        <vo_id>VO_0011145</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>16445023</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279241
CDD:213392
CDD:213897</xrefs>
        <taxonomy_id>11072</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope protein</protein_name>
        <protein_pi>7.88</protein_pi>
        <protein_weight>49812.26</protein_weight>
        <protein_length>577</protein_length>
        <protein_note>Flavivirus glycoprotein, central and dimerization domains; pfam00869</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAK31640.1 envelope protein, partial [Japanese encephalitis virus]
FNCLGMGNRDFIEGASGATWVDLVLEGDSCLTIMANDKPTLDVRMINIEASQLAEVRSYCYHASVTDIST
VARCPTTGEAHNEKRADSSYVCKQGFTDRGWGNGCGLFGKGSIDTCAKFSCTSKAIGRTIQPENIKYKVG
IFVHGATTSENHGNYSAQVGASQAAKFTVTPNAPSITLKLGDYGEVTLDCEPRSGLNTEAFYVMTVGSKS
FLVHREWFHDLALPWTSPSSTAWRNRELLMEFEEAHATKQSVVALGSQEGGLHQALAGAIVVEYSSSVKL
TSGHLKCRLKMDKLALKGTTYGMCTEKFSFAKNPADTGHGTVVIELSYSGSDGPCKIPIVSVASLNDMTP
VGRLVTVNPFVATSSANSKVLVEMEPPFGDSYIVVGRGDKQINHHWHKAGSTLGKAFSTTLKGAQRLAAL
GDTAWDFGSIGGVFNSIGKAVHQVFGGAFRTLFGGMSWITQGLMGALLLWMGVNARDRSIALAFLATGGV
LVFLATNVHA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Researchers constructed a recombinant pseudotype baculovirus encoding the JEV envelope (E) protein and demonstrated that it could elicit high protective immunity in mice.  Intramuscular injections of BV-G-E at various doses into mice produced higher levels of JEV-specific neutralizing antibodies, IFN-gamma and better protective efficacy against a lethal challenge with JEV than that of pc-E. Furthermore, BV-G-E could elicit a higher level of cellular immunity response and provide equal protective efficacy against JEV challenge compared to inactivated vaccine [Ref1157:Li et al., 2009].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1">
        <gene_name>Ifng (Interferon gamma)</gene_name>
        <strain>Mouse</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>15978</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>33468859</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>NM_008337</gene_refseq>
        <protein_refseq>NP_032363.1</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>MGI:107656; UniProt:P01580</xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name></protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA
ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA
GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA
GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT
AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC
AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT
GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC
AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC
GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA
AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG
AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC
AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT
TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC
TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT
ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG
GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC
AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC
TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA
AGTATACCTTTGCAACC</dna_sequence>
        <protein_sequence>>gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus]
MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI
ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ
LLPESSLRKRKRSRC</protein_sequence>
        <phi_function></phi_function>
        <phi_annotation>IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria.</phi_annotation>
        <phi_function2>Vaximmutor</phi_function2>
        <phi_annotation2>The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes  [Ref2101:Wang et al., 2009].</phi_annotation2>
    </gene>
	<gene gene_id="gene1727">
        <gene_name>M protein</gene_name>
        <strain>Japanese encephalitis virus strain TS3306</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>4572323</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279856</xrefs>
        <taxonomy_id>11072</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>M protein</protein_name>
        <protein_pi>5.84</protein_pi>
        <protein_weight>10361.74</protein_weight>
        <protein_length>156</protein_length>
        <protein_note>isolated from the Torres Strait</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAD23744.1 M protein, partial [Japanese encephalitis virus]
MKLSNFQGKLLMTVNNTDIADVIVIPTSKGENRCWVRAIDVGYMCEDTITYECPKLTTGNDPEDVDCWCD
NQEVYIQYGRCTRTRHSKRSRR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene556">
        <gene_name>NS1</gene_name>
        <strain>Japanese encephalitis virus</strain>
        <vo_id>VO_0011147</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>18418672</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279316</xrefs>
        <taxonomy_id>11072</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>NS1 protein</protein_name>
        <protein_pi>8.12</protein_pi>
        <protein_weight>16884.93</protein_weight>
        <protein_length>218</protein_length>
        <protein_note>isolated from porcine sera</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAL68990.1 NS1 protein, partial [Japanese encephalitis virus]
ELIIPHTIAGPRSKHNRREGYKTQNQGPWDENGIVLDFDYCPGTKVTITEDCGKRGPSIRTTTDSGKLIT
DWCCRSCSLPPLRFRTENGCWYGMEIRPVRHDETTLVRSQVDAFNGEMIDPFQLGLLVMFLATQEVLRKR
WTARLTIPAVL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Balb/c mice and swine vaccinated with TK(-)/gG(-)/NS1(+) expressing NS1 protein of JEV could confer protective immunity against lethal challenge of the virulent PRV Ea strain and develop a good humoral and cellular immune response against JEV [Ref1159:Xu et al., 2004].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene557">
        <gene_name>NS3</gene_name>
        <strain>Japanese encephalitis virus</strain>
        <vo_id>VO_0011148</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>27696332</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279317
CDD:214692
CDD:284962
CDD:238005
CDD:304359
CDD:238034</xrefs>
        <taxonomy_id>11072</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>non-structural protein NS3</protein_name>
        <protein_pi>7.14</protein_pi>
        <protein_weight>64684.98</protein_weight>
        <protein_length>699</protein_length>
        <protein_note>proteinase and putative helicase</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>NP_775670.1 non-structural protein NS3 [Japanese encephalitis virus]
GGVFWDTPSPKPCSKGDTTTGVYRIMARGILGTYQAGVGVMYENVFHTLWHTTRGAAIMSGEGKLTPYWG
SVKEDRIAYGGPWRFDRKWNGTDDVQVIVVEPGKAAVNIQTKPGVFRTPFGEVGAVSLDYPRGTSGSPIL
DSNGDIIGLYGNGVELGDGSYVSAIVQGDRQEEPVPEAYTPNMLRKRQMTVLDLHPGSGKTRKILPQIIK
DAIQQRLRTAVLAPTRVVAAEMAEALRGLPVRYQTSAVQREHQGNEIVDVMCHATLTHRLMSPNRVPNYN
LFVMDEAHFTDPASIAARGYIATKVELGEAAAIFMTATPPGTTDPFPDSNAPIHDLQDEIPDRAWSSGYE
WITEYAGKTVWFVASVKMGNEIAMCLQRAGKKVIQLNRKSYDTEYPKCKNGDWDFVITTDISEMGANFGA
SRVIDCRKSVKPTILEEGEGRVILGNPSPITSASAAQRRGRVGRNPNQVGDEYHYGGATSEDDSNLAHWT
EAKIMLDNIHMPNGLVAQLYGPEREKAFTMDGEYRLRGEEKKNFLELLRTADLPVWLAYKVASNGIQYTD
RRWCFDGPRTNAILEDNTEVEIVTRMGERKILKPRWLDARVYADHQALKWFKDFAAGKR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Researchers constructed plasmid DNAs encoding JE virus proteins.  Cytotoxic T lymphocytes (CTLs) were induced by NS3 in a mouse model.  Three immunizations with pUJENS3 provided a 50% partial protection from a lethal dose of JE virus [Ref1160:Konishi et al., 2003].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene558">
        <gene_name>NS5</gene_name>
        <strain>Japanese encephalitis virus</strain>
        <vo_id>VO_0011149</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>158702649</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279336</xrefs>
        <taxonomy_id>11072</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>NS5</protein_name>
        <protein_pi>9.89</protein_pi>
        <protein_weight>8854.45</protein_weight>
        <protein_length>135</protein_length>
        <protein_note>Flavivirus RNA-directed RNA polymerase; pfam00972</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>ABW77689.1 NS5, partial [Japanese encephalitis virus]
KREKKPGEFGKAKGSRAIWFMWLGARYLEFEALGFLNEDHWLSRENSGGGVEGSGVQKLGYILRDIAGKQ
GGKMYAD

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS5 in a mouse model. Three immunizations with pUJENS5 provided a 57% partial protection from a lethal dose of JE virus [Ref1160:Konishi et al., 2003].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene555">
        <gene_name>PrM</gene_name>
        <strain>Japanese encephalitis virus</strain>
        <vo_id>VO_0011146</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>90019439</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279856</xrefs>
        <taxonomy_id>11072</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>PrM</protein_name>
        <protein_pi>4.01</protein_pi>
        <protein_weight>8654.05</protein_weight>
        <protein_length>138</protein_length>
        <protein_note>Flavivirus polyprotein propeptide; pfam01570</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>ABD84370.1 PrM, partial [Japanese encephalitis virus]
VIACVGAMKLSNFQGKLLMTINKTDIADVIVIPTSKGENRCWVRAIDVGYMCEDTITYECPKLTMGNDPE
DVDCWCDNQE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Researchers established a simple and effective method for DNA immunization against Japanese encephalitis virus (JEV) infection with plasmids encoding the viral PrM and E proteins and colloidal gold.   After being inoculated twice, BALB/c mice were found to resist challenge with 100,000 times the 50% lethal dose (LD(50)) of JEV (Beijing-1 strain) even when immunized with a relatively small dose of 0.5 micro g of plasmid DNA [Ref1158:Zhao et al., 2003].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<reference reference_id="reference917">
		<reference_name>FDA: Ixiaro</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA: Ixiaro</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm179132.htm</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference747">
		<reference_name>FDA: JE-Vax</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA: JE-Vax vaccine information</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094048.htm</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4973">
		<reference_name>Hua et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hua RH, Liu LK, Huo H, Li YN, Guo LP, Wang XL, Qin CF, Bu ZG</authors>
		<title>Comprehensive mapping of a novel NS1 epitope conserved in flaviviruses within the Japanese encephalitis virus serocomplex</title>
		<year>2014</year>
		<volume>185</volume>
		<issue></issue>
		<pages>103-109</pages>
		<journal_book_name>Virus research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3293">
		<reference_name>Konishi et al., 1992</reference_name>
		<reference_type>journal</reference_type>
		<authors>Konishi E, Pincus S, Paoletti E, Laegreid WW, Shope RE, Mason PW</authors>
		<title>A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine</title>
		<year>1992</year>
		<volume>190</volume>
		<issue>1</issue>
		<pages>454-458</pages>
		<journal_book_name>Virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1160">
		<reference_name>Konishi et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Konishi E, Ajiro N, Nukuzuma C, Mason PW, Kurane I</authors>
		<title>Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice</title>
		<year>2003</year>
		<volume>21</volume>
		<issue>25-26</issue>
		<pages>3675-3683</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2719">
		<reference_name>Kulkarni et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kulkarni R, Sapkal G, Gore M</authors>
		<title>Evaluation of Japanese encephalitis virus polytope DNA vaccine candidate in BALB/c mice</title>
		<year>2012</year>
		<volume>170</volume>
		<issue>1-2</issue>
		<pages>118-125</pages>
		<journal_book_name>Virus research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1157">
		<reference_name>Li et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Li Y, Ye J, Cao S, Xiao S, Zhao Q, Liu X, Jin M, Chen H</authors>
		<title>Immunization with pseudotype baculovirus expressing envelope protein of Japanese encephalitis virus elicits protective immunity in mice</title>
		<year>2009</year>
		<volume>11</volume>
		<issue>1</issue>
		<pages>57-65</pages>
		<journal_book_name>The journal of gene medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4994">
		<reference_name>Qian et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Qian P, Zhi X, Wang B, Zhang H, Chen H, Li X</authors>
		<title>Construction and immune efficacy of recombinant pseudorabies virus expressing PrM-E proteins of Japanese encephalitis virus genotype ?</title>
		<year>2015</year>
		<volume>12</volume>
		<issue></issue>
		<pages>214</pages>
		<journal_book_name>Virology journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3289">
		<reference_name>Raengsakulrach et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V, Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn DW</authors>
		<title>Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys</title>
		<year>1999</year>
		<volume>60</volume>
		<issue>3</issue>
		<pages>343-349</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2332">
		<reference_name>Sheets et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL</authors>
		<title>Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts</title>
		<year>2006</year>
		<volume>91</volume>
		<issue>2</issue>
		<pages>610-619</pages>
		<journal_book_name>Toxicological sciences : an official journal of the Society of Toxicology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference720">
		<reference_name>Wiki: Japanese encephalitis</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>Wiki: Japanese encephalitis</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://en.wikipedia.org/wiki/Japanese_encephalitis</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2720">
		<reference_name>Wu et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wu CJ, Li TL, Huang HW, Tao MH, Chan YL</authors>
		<title>Development of an effective Japanese encephalitis virus-specific DNA vaccine</title>
		<year>2006</year>
		<volume>8</volume>
		<issue>11</issue>
		<pages>2578-2586</pages>
		<journal_book_name>Microbes and infection / Institut Pasteur</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1159">
		<reference_name>Xu et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xu G, Xu X, Li Z, He Q, Wu B, Sun S, Chen H</authors>
		<title>Construction of recombinant pseudorabies virus expressing NS1 protein of Japanese encephalitis (SA14-14-2) virus and its safety and immunogenicity</title>
		<year>2004</year>
		<volume>22</volume>
		<issue>15-16</issue>
		<pages>1846-1853</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1161">
		<reference_name>Yasuda et al., 1990</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yasuda A, Kimura-Kuroda J, Ogimoto M, Miyamoto M, Sata T, Sato T, Takamura C, Kurata T, Kojima A, Yasui K</authors>
		<title>Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus</title>
		<year>1990</year>
		<volume>64</volume>
		<issue>6</issue>
		<pages>2788-2795</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1158">
		<reference_name>Zhao et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhao Z, Wakita T, Yasui K</authors>
		<title>Inoculation of plasmids encoding Japanese encephalitis virus PrM-E proteins with colloidal gold elicits a protective immune response in BALB/c mice</title>
		<year>2003</year>
		<volume>77</volume>
		<issue>7</issue>
		<pages>4248-4260</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
</VIOLIN>


